![Chhattisgarh-Born [U]Defy Expands Across India After Reaching 600 Plus Retail Counters and 16,000 Customers-TBT](https://theblunttimes.in/wp-content/uploads/2026/06/PNN-19.jpg "Chhattisgarh-Born [U]Defy Expands Across India After Reaching 600 Plus Retail Counters and 16,000 Customers")
Hetero Healthcare Expands Oncology Portfolio with Perzea Launch in Collaboration with Enzene Biosciences
Hetero Healthcare and Enzene Biosciences have introduced Perzea to expand affordable access to pertuzumab therapy for HER2+ breast cancer, leveraging EnzeneX™ technology.
Hetero Healthcare and Enzene launched Perzea, India’s most affordable Pertuzumab biosimilar
Table Of Content
Hyderabad (Telangana) [India], September 25: Hetero Healthcare Limited, in strategic partnership with Enzene Biosciences, has announced the launch of Perzea, India’s most affordable biosimilar of Pertuzumab. This advanced therapy for HER2-positive breast cancer underscores the shared commitment of both companies to expanding access to cutting-edge cancer treatments and strengthening oncology care in the country.
Innovation Meets Affordability
Pertuzumab plays a vital role in the standard of care for HER2-positive breast cancer worldwide. By leveraging Enzene’s patented EnzeneX™ technology, Perzea becomes not only affordable but also reliable in terms of quality and production efficiency. This innovation-driven partnership sets new standards for biologics in India.
Speaking on the occasion, Mr. M. Srinivas Reddy, Managing Director of Hetero Healthcare Limited, said:
“At Hetero Healthcare, we believe innovation must be purposeful. With Perzea, we integrate Enzene’s technology with our vision of affordability, ensuring patients in India can access advanced oncology medicines without compromise.”
Strengthening India’s Biopharma Ecosystem
The launch of Perzea highlights India’s growing capabilities in biologics manufacturing and biosimilar development. It also reinforces Hetero Healthcare’s dedication to delivering cutting-edge yet cost-effective therapies across oncology and other therapeutic areas.
About Hetero Healthcare
Hetero Healthcare Limited is recognised for its wide-ranging portfolio in oncology, critical care, and chronic disease management. The company continues to pioneer initiatives that make oncology medicines in India more accessible. Visit: www.heterohealthcare.com
About Enzene Biosciences
Enzene is a next-generation biologics manufacturer and the first to validate a fully connected continuous manufacturing (FCCM™) platform for commercial biologics supply. Its operations in Pune (India) and New Jersey (USA) focus on biologics innovation and affordability. Visit: www.enzene.com
Disclaimer: The article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.
